Last visit was: 24 Apr 2024, 10:08 It is currently 24 Apr 2024, 10:08

Close
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

Customized
for You

we will pick new questions that match your level based on your Timer History

Track
Your Progress

every week, we’ll send you an estimated GMAT score based on your performance

Practice
Pays

we will pick new questions that match your level based on your Timer History
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
Close
Request Expert Reply
Confirm Cancel
SORT BY:
Date
Tags:
Show Tags
Hide Tags
Manager
Manager
Joined: 13 Oct 2016
Posts: 194
Own Kudos [?]: 769 [12]
Given Kudos: 418
Concentration: Operations, Leadership
GMAT 1: 600 Q44 V28
Send PM
Most Helpful Reply
Manager
Manager
Joined: 01 Feb 2018
Posts: 84
Own Kudos [?]: 209 [6]
Given Kudos: 769
Location: India
GMAT 1: 700 Q47 V38
WE:Consulting (Consulting)
Send PM
General Discussion
Manager
Manager
Joined: 04 Apr 2015
Posts: 233
Own Kudos [?]: 134 [3]
Given Kudos: 269
GMAT 1: 650 Q49 V31
GPA: 3.59
Send PM
Manager
Manager
Joined: 04 Apr 2015
Posts: 233
Own Kudos [?]: 134 [1]
Given Kudos: 269
GMAT 1: 650 Q49 V31
GPA: 3.59
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
1
Kudos
Sreyoshi007 wrote:
5 mins, including time to read the passage, 5/6 correct
1.
Quote:
Q1. The author questions the results of Protocol 076 for which of the following reasons?

A. The number of T-cells was not considered in choosing subjects for the study.
B. The trial was discontinued, and the control group of women on placebo was shifted to AZT.
C. Seventy-five percent of babies born to women in the placebo group were free of infection with HIV.
D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies.
E. The exact mechanism and timing of HIV transmission are unknown.


Refer to the following lines in the passage :
Quote:
Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates. Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission.

Based on this, option D makes the most sense and is the right answer.

2.
Quote:
Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

I got this one wrong, I was confused between options B and E and incorrectly chose B. But on re-reading the passage I noticed the following lines

Quote:
Since the majority of the babies born to HIV-positive women are HIV-negative, and since HIV may mutate into drug-resistant strains following a break in medication, the value of a short term “zap” with AZT becomes suspect.

So, from this we can understand why E is better. For women who have not taken AZT, the medication will not be resistant and hence will work. I am not sure if my reasoning is correct, workout please clarify.

3.
Quote:
Q3. The passage implies that the “viral loads” of the subjects in the study are significant because

A. all the subjects had relatively high viral loads, so the study’s results may not apply to other groups of women.
B. the viral loads of babies whose mothers had received the placebo were just as high as those of babies whose mothers had received AZT.
C. viral load must be measured if researchers are to understand the exact mechanism and timing of transmission of HIV.
D. the viral loads of women in the placebo group may have been different from those of women in the AZT group.
E. viral load may be a critical factor in determining transmission, but the researchers wrongly assumed that it was the only factor.


Again referring to the following lines from the passage:
Quote:
Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates. Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission.


The passage mentions that the viral loads were significant because they cast a doubt on the validity of the study's results. This further can imply that the viral load of the group of women in the two groups may be different and hence they are significant.
Answer option D is correct.

4.
Quote:
Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment.
B. expose medical errors caused by the careless methodology in an important clinical trial.
C. raise doubts about a course of treatment based on a groundbreaking study.
D. describe the process of vertical transmission of HIV and suggest preventive therapy.
E. evaluate treatment possibilities for pregnant women with HIV.


The primary purpose of the passage is to raise doubts on the validity of a particular treatment. This is best captured in answer option C.

5.
Quote:
Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another.
B. Recommendations based on a conditional experiment must be qualified.
C. The study should not have been prematurely ended.
D. Clinical trials that may harm patients are unethical.
E. No HIV-positive woman should take AZT during pregnancy.


We can solve this by POE.
A. This is too generic and this has not been mentioned in the passage. We can eliminate A.
B. Yes, this makes sense. We can infer from the passage that results from an experiment need to be qualified. Correct.
C. The passage states that the study was prematurely ended but nowhere is the judgement made whether the study should not have ended prematurely or not. Eliminate C.
D. Not mentioned in the passage, out of scope. Eliminate.
E. Too extreme, not mentioned that no HIV-positive woman should take AZT during pregnancy.

B is the correct answer.

6.
Quote:
Q6. The primary function of the second paragraph is to

A. refute issues.
B. evaluate solutions.
C. describe results.
D. support action.
E. identify problems.


The second paragraph gives us the reasons why the result of the study is debatable. Refer to lines :
Quote:
The validity of the study’s results, however, is debatable.

Considering this, answer option E is correct as we do identify the problems.

If someone could clarify my reasoning for Q2, it would be great!
Thanks,
:)

Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

the author mentions in start of second para : high T cells and less than 6 months duration of AZT

A. A woman who has used the regimen successfully in a previous pregnancy--opposite
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born---opposite
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status--- no correlation
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy--- no mention about this
E. A woman whose T-cell count is not low and who has not taken AZT before
Intern
Intern
Joined: 22 Jan 2018
Posts: 6
Own Kudos [?]: 2 [0]
Given Kudos: 6
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
Why the answer for Q1 is D not E as option E is clerarly stated in para last lines.

Posted from my mobile device
Manager
Manager
Joined: 04 Apr 2015
Posts: 233
Own Kudos [?]: 134 [0]
Given Kudos: 269
GMAT 1: 650 Q49 V31
GPA: 3.59
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
naina0001 wrote:
Why the answer for Q1 is D not E as option E is clerarly stated in para last lines.

Posted from my mobile device


As far as I understood it was not option E although being stated is the reason for the study being disqualified but lack of considering the rates in the study was the reason so D is best
Manager
Manager
Joined: 23 Dec 2011
Posts: 66
Own Kudos [?]: 81 [0]
Given Kudos: 131
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

Can someone please explain why E is correct, based on the following statements from the passage I can understand that “A woman whose T-cell count is not low” is correct -
Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months
But the second part of the answer choice says that “who has not taken AZT before”, and the from the above statements from the passage it says that “who had previously taken AZT for less than six months”
Retired Moderator
Joined: 23 Sep 2015
Posts: 1267
Own Kudos [?]: 5650 [2]
Given Kudos: 416
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
2
Kudos
P1 - AZT its usefulness
P2 - contrast from P1;
P3 - more bad roles of AZT

Main point - AZT is good in certain case, but bad in other many cases.

Q1. The author questions the results of Protocol 076 for which of the following reasons?
this is done in p2 and p3

D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies. - yes ; in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates.
------------------------------------------------
Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?
answer should be in P1/p2. ---- women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV.

A. A woman who has used the regimen successfully in a previous pregnancy - no
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born - no
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status - no
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy - no
E. A woman whose T-cell count is not low and who has not taken AZT before - yes

-----------------------------------------------

Q3. The passage implies that the viral loads” of the subjects in the study are significant because
whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates.

The trial found that administration of AZT to HIV-positive women during pregnancy and delivery, and to their babies after birth, reduced the transmission of HIV to the infants by two thirds, compared with a placebo.

D. the viral loads of women in the placebo group may have been different from those of women in the AZT group. - y

-----------------------------------------------

Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment. - no
B. expose medical errors caused by the careless methodology in an important clinical trial. - yes but aim of author is to reject AZt.
C. raise doubts about a course of treatment based on a groundbreaking study. - more close to main point.
D. describe the process of vertical transmission of HIV and suggest preventive therapy. - no
E. evaluate treatment possibilities for pregnant women with HIV. - no

----------------------------------------------
Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another. - too braod
B. Recommendations based on a conditional experiment must be qualified. - closest
C. The study should not have been prematurely ended. - no; not mentioned.
D. Clinical trials that may harm patients are unethical. - no; not mentioned.
E. No HIV-positive woman should take AZT during pregnancy. - no; too braod

----------------------------------------------
Q6. The primary function of the second paragraph is to
Contrast the p1

E. identify problems. - has to be this.
Manager
Manager
Joined: 23 Aug 2016
Posts: 98
Own Kudos [?]: 158 [1]
Given Kudos: 818
Location: India
Concentration: Finance, Strategy
GMAT 1: 660 Q49 V31
GPA: 2.84
WE:Other (Energy and Utilities)
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
1
Kudos
Kritesh wrote:
A regimen of intrauterine AZT (zidovudine) as a means of reducing the chances of HIV transmission from mother to child was first described in a study known as Protocol 076, the results of which were published in the New England Journal of Medicine in November 1994. The trial found that administration of AZT to HIV-positive women during pregnancy and delivery, and to their babies after birth, reduced the transmission of HIV to the infants by two thirds, compared with a placebo. The study was acclaimed as one of the first successful instances of a prophylaxis preventing HIV transmission—particularly “vertical” transmission, or transmission from mothers to infants. The study, prematurely ended so that all the subjects on placebos could be switched to AZT, led to the recommendation that all pregnant women with HIV take AZT.

The validity of the study’s results, however, is debatable. Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV. Moreover, the study administered large doses of AZT without examining whether lower doses, more economically feasible for uninsured or under insured women, might be effective. Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates. Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission.

Also, the study did not consider the long term impact of AZT, which is toxic, on the babies themselves. There have been few studies of AZT’s effect on HIV-positive infants and none on its effects on uninfected babies. Since the majority of the babies born to HIV-positive women are HIV-negative, and since HIV may mutate into drug-resistant strains following a break in medication, the value of a short term “zap” with AZT becomes suspect.
Q1. The author questions the results of Protocol 076 for which of the following reasons?

A. The number of T-cells was not considered in choosing subjects for the study.
B. The trial was discontinued, and the control group of women on placebo was shifted to AZT.
C. Seventy-five percent of babies born to women in the placebo group were free of infection with HIV.
D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies.
E. The exact mechanism and timing of HIV transmission are unknown.

Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

Q3. The passage implies that the “viral loads” of the subjects in the study are significant because

A. all the subjects had relatively high viral loads, so the study’s results may not apply to other groups of women.
B. the viral loads of babies whose mothers had received the placebo were just as high as those of babies whose mothers had received AZT.
C. viral load must be measured if researchers are to understand the exact mechanism and timing of transmission of HIV.
D. the viral loads of women in the placebo group may have been different from those of women in the AZT group.
E. viral load may be a critical factor in determining transmission, but the researchers wrongly assumed that it was the only factor.

Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment.
B. expose medical errors caused by the careless methodology in an important clinical trial.
C. raise doubts about a course of treatment based on a groundbreaking study.
D. describe the process of vertical transmission of HIV and suggest preventive therapy.
E. evaluate treatment possibilities for pregnant women with HIV.

Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another.
B. Recommendations based on a conditional experiment must be qualified.
C. The study should not have been prematurely ended.
D. Clinical trials that may harm patients are unethical.
E. No HIV-positive woman should take AZT during pregnancy.

Q6. The primary function of the second paragraph is to

A. refute issues.
B. evaluate solutions.
C. describe results.
D. support action.
E. identify problems.




Here are my 2 cents-

Q1. The author questions the results of Protocol 076 for which of the following reasons?

A. The number of T-cells was not considered in choosing subjects for the study-Out of scope
B. The trial was discontinued, and the control group of women on placebo was shifted to AZT.-True but not the the reason author questions the study
C. Seventy-five percent of babies born to women in the placebo group were free of infection with HIV.-not seventy five percent but 66.66%(2/3) not (3/4).
D. Different transmission rates could have been influenced by different amounts of HIV in the women’s bodies-Correct"Further, the trial design did not account for important variables: in particular, whether the subjects’ viral load—the amount of HIV in their bodies—might have contributed to the difference in transmission rates."
E. The exact mechanism and timing of HIV transmission are unknown.

Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy-No author would discourage such a use!
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born-No author would discourage such a use!
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status-Out of scope
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy-No author would discourage such a use!
E. A woman whose T-cell count is not low and who has not taken AZT before-Correct, refer"Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV."

Q3. The passage implies that the “viral loads” of the subjects in the study are significant because

A. all the subjects had relatively high viral loads, so the study’s results may not apply to other groups of women-Wrong! no where mentioned.
B. the viral loads of babies whose mothers had received the placebo were just as high as those of babies whose mothers had received AZT.-Wrong! no where mentioned.
C. viral load must be measured if researchers are to understand the exact mechanism and timing of transmission of HIV.-True but not the answer
D. the viral loads of women in the placebo group may have been different from those of women in the AZT group.-Correct refer passage.
E. viral load may be a critical factor in determining transmission, but the researchers wrongly assumed that it was the only factor.-Incorrect, "WRONGLY ASSUMED" is no where inferred.

Q4. The primary purpose of the passage is to

A. document recent problems with HIV and AIDS treatment.-Wrong! nothing about AIDS!
B. expose medical errors caused by the careless methodology in an important clinical trial-Wrong! Careless methodology is too strong.
C. raise doubts about a course of treatment based on a groundbreaking study.-Correct, Author details a path breaking process and goes on to infer its limitations and doubts on the validity of study!
D. describe the process of vertical transmission of HIV and suggest preventive therapy.-Partial scope
E. evaluate treatment possibilities for pregnant women with HIV.-Partial scope.

Q5. The author of the passage would be most likely to agree with which of the following statements?

A. Medications harmful to one group of patients are probably not harmful to another.-Nowhere mentioned
B. Recommendations based on a conditional experiment must be qualified.-Correct, Author supports that the trial should be qualified !
C. The study should not have been prematurely ended.-Study did ended prematurely but author supports or refutes is no where mentioned.
D. Clinical trials that may harm patients are unethical.-Nowhere mentioned
E. No HIV-positive woman should take AZT during pregnancy.-Nowhere mentioned

Q6. The primary function of the second paragraph is to

A. refute issues.-Wrong! no issues are refuted.
B. evaluate solutions.-Umm, kinda right! Keep it for now!
C. describe results.-NO results are described rather the basis on which result is reached is described.
D. support action.-No suppor to action.
E. identify problems.-Kinda right! author does talks about problems! Correct !

I will select E over B.

[/box_in][/box_out][/quote]
Manager
Manager
Joined: 23 Aug 2016
Posts: 98
Own Kudos [?]: 158 [0]
Given Kudos: 818
Location: India
Concentration: Finance, Strategy
GMAT 1: 660 Q49 V31
GPA: 2.84
WE:Other (Energy and Utilities)
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
workout wrote:

+1 kudos to the posts containing answer explanations of all questions



Hi workout,

Please help me understand question no. 6!

Q6. The primary function of the second paragraph is to

A. refute issues.-Wrong! no issues are refuted.
B. evaluate solutions.-Umm, kinda right! Keep it for now!
C. describe results.-NO results are described rather the basis on which result is reached is described.
D. support action.-No suppor to action.
E. identify problems.-Kinda right! author does talks about problems! Correct !

I was terribly divided between B and E but fortunately selected E but what is the major flaw in B?

Need your advice please workout !
Manager
Manager
Joined: 03 Dec 2018
Posts: 133
Own Kudos [?]: 18 [0]
Given Kudos: 93
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
Please Explain Q3. C vs D
Q5) B vs C
Intern
Intern
Joined: 26 Nov 2018
Status:when you say,"I can or I can't", Both times you are right!
Posts: 21
Own Kudos [?]: 21 [0]
Given Kudos: 17
Location: India
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
mallya12 wrote:
Please Explain Q3. C vs D
Q5) B vs C




Q3. C vs D

"Since the exact mechanism and timing of vertical transmission of the HIV virus are unknown, it cannot be ruled out that viral load influences rates of vertical transmission."
It implies Viral load could be the factor.
what if we can find the exact mechanism in which viral load did not play any role; Hence, statement 'C' which says viral load must be studied is wrong.
Option D: says viral load could be the factor: which is exactly passage implies.

Q5) B vs C

research can be prematurely ended therefore scientists ended the research, but research should be qualified to be prematurely ended.

Option B: research should be qualified

Hope this will help you.


Thanks = Kudos
Intern
Intern
Joined: 03 Aug 2019
Posts: 4
Own Kudos [?]: 1 [0]
Given Kudos: 108
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
egmat Souvik can you please explain question no 2?
Retired Moderator
Joined: 05 May 2016
Posts: 792
Own Kudos [?]: 683 [1]
Given Kudos: 1316
Location: India
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
1
Kudos
KADELSANJAY wrote:
egmat Souvik can you please explain question no 2?



Hi KADELSANJAY,

Let me know if this helps.


Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

Correct Answer : E ,
Explanation: as mentioned in the passage: "The validity of the study’s results, however, is debatable. Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV.", implying that author is least likely to challenge benefits of intrauterine AZT, for a woman whose T-cell count is high and who has either not taken AZT before or has taken AZT for less than 6 months.
Option A: incorrect, there could be multiple factors for the successful application in previous pregnancy, also nothing has been mentioned in the passage, w.r.t the same.
Option B: incorrect, opposite of what's mentioned in the argument could be true.
Option C, D: not relevant.


Thanks.
Intern
Intern
Joined: 20 Mar 2020
Posts: 48
Own Kudos [?]: 8 [0]
Given Kudos: 177
Send PM
A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
bm2201 wrote:
KADELSANJAY wrote:
egmat Souvik can you please explain question no 2?



Hi KADELSANJAY,

Let me know if this helps.


Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

Correct Answer : E ,
Explanation: as mentioned in the passage: "The validity of the study’s results, however, is debatable. Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV.", implying that author is least likely to challenge benefits of intrauterine AZT, for a woman whose T-cell count is high and who has either not taken AZT before or has taken AZT for less than 6 months.
Option A: incorrect, there could be multiple factors for the successful application in previous pregnancy, also nothing has been mentioned in the passage, w.r.t the same.
Option B: incorrect, opposite of what's mentioned in the argument could be true.
Option C, D: not relevant.


Thanks.


For me, confusion is between A and E.
I discarded E for the following reasons:
1. "not low" does not mean "high".
2. "who had previously taken AZT for less than six months" does not imply "who had not taken AZT at all".

For Option A, if the regime might have worked previously, then they might have been within the similar conditions as per other subjects, though those conditions might change in future but it was the remaining option which sounded right to me and I did not found author strictly mentioning anything against it.

How to reliably choose the correct answer in such situations?
Retired Moderator
Joined: 05 May 2016
Posts: 792
Own Kudos [?]: 683 [1]
Given Kudos: 1316
Location: India
Send PM
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
1
Kudos
thecoronafever wrote:
bm2201 wrote:
KADELSANJAY wrote:
egmat Souvik can you please explain question no 2?



Hi KADELSANJAY,

Let me know if this helps.


Q2. The author of this passage would be LEAST likely to challenge the benefits of intrauterine AZT for which of the following HIV-positive women and/or their future children?

A. A woman who has used the regimen successfully in a previous pregnancy
B. A woman whose T-cell count is dangerously low and who plans to continue taking AZT after her baby is born
C. A woman who is matched with the study’s subjects in terms of ethnicity and socioeconomic status
D. A woman who has lost a previous infant to HIV and who wants to be sure that her next child is healthy
E. A woman whose T-cell count is not low and who has not taken AZT before

Correct Answer : E ,
Explanation: as mentioned in the passage: "The validity of the study’s results, however, is debatable. Since Protocol 076 examined only women who had fairly high numbers of T-cells—the white blood cells that coordinate immune response—and who had previously taken AZT for less than six months, the same regimen might not succeed for other pregnant women with HIV.", implying that author is least likely to challenge benefits of intrauterine AZT, for a woman whose T-cell count is high and who has either not taken AZT before or has taken AZT for less than 6 months.
Option A: incorrect, there could be multiple factors for the successful application in previous pregnancy, also nothing has been mentioned in the passage, w.r.t the same.
Option B: incorrect, opposite of what's mentioned in the argument could be true.
Option C, D: not relevant.


Thanks.


For me, confusion is between A and E.
I discarded E for the following reasons:
1. "not low" does not mean "high".
2. "who had previously taken AZT for less than six months" does not imply "who had not taken AZT at all".

For Option A, if the regime might have worked previously, then they might have been within the similar conditions as per other subjects, though those conditions might change in future but it was the remaining option which sounded right to me and I did not found author strictly mentioning anything against it.

How to reliably choose the correct answer in such situations?


Hi thecoronafever,

The author is least likely to agree with Option A, and we can infer the same from the last para:
"Also, the study did not consider the long term impact of AZT, which is toxic, on the babies themselves. There have been few studies of AZT’s effect on HIV-positive infants and none on its effects on uninfected babies.", implying that after effects of AZT are harmful for the babies, and author provides studies to prove the same, in turn implying that benefits of AZT are not likely to be present in the children of the women with successful pregnancies.

For Option E, its true that not low, does not mean high and that "who had previously taken AZT for less than six months" does not imply "who had not taken AZT at all", but their mention in the passage, leaves us with possibilities, which are not being challenged, implying that author is least likely to challenge them.


For such kinds of questions, always look for either mentions or evidences that challenge view presented in the options, because author would be unlikely to dispute them. Even in the question above, all of the options have been refuted by the author in some or the other way, so looking for the best fit would lead to a correct answer.


Hope this Helps.
Thanks.
GMAT Club Bot
Re: A regimen of intrauterine AZT (zidovudine) as a means of reducing the [#permalink]
Moderators:
GMAT Club Verbal Expert
6917 posts
GMAT Club Verbal Expert
238 posts
GRE Forum Moderator
13957 posts

Powered by phpBB © phpBB Group | Emoji artwork provided by EmojiOne